Company intelligence / Profile preview

DBV Technologies

Ownership: Public · DBVT
Development stage: Other

Overview

The company's lead product, VIASKIN Peanut patch (DBV712), has shown positive results in Phase 3 trials. In the EPITOPE study for toddlers ages 1-3 years, 67% of patients treated with Viaskin Peanut 250 µg were considered responders with significant increases in peanut tolerance. The company has announced plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2026.

Therapeutic areas: GastroenterologyImmunology
Modalities: Epicutaneous immunotherapy (EPIT)
Industry: Biotech

Drug pipeline

11 assets

DBV712 Viaskin®

10 more assets in the full pipeline.

Partnerships

Children's Hospital of Philadelphia (CHOP)

Financials

Market cap: $234.4M
Total revenue: $0
Enterprise value: $89.4M

Beyond the preview

Go deeper on DBV Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DBV Technologies.